Shattuck Labs (NASDAQ:STTK) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Key Points

• Shattuck Labs reported quarterly EPS of ($0.13), beating analyst expectations of ($0.14) by $0.01 and improving from ($0.27) per share a year earlier.
• The stock jumped 9.4% after the earnings release, trading as high as $6.85 with heavier-than-average volume.
• Analyst sentiment remains mostly positive, with multiple firms raising targets and the consensus rating listed as Moderate Buy with a $13.00 price target.

Shattuck Labs (NASDAQ:STTK - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.01, FiscalAI reports. During the same quarter in the previous year, the company posted ($0.27) EPS.

Shattuck Labs Stock Up 9.4%

Shares of Shattuck Labs stock traded up $0.59 during trading hours on Friday, hitting $6.85. The company's stock had a trading volume of 1,574,131 shares, compared to its average volume of 626,682. Shattuck Labs has a 1-year low of $0.71 and a 1-year high of $8.33. The business has a fifty day moving average of $6.34 and a 200 day moving average of $4.29. The company has a market capitalization of $517.74 million, a PE ratio of -8.90 and a beta of 1.18.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Shattuck Labs in a research note on Thursday, January 22nd. TD Cowen reaffirmed a "buy" rating on shares of Shattuck Labs in a research note on Friday, March 6th. Wedbush increased their price target on shares of Shattuck Labs from $8.00 to $11.00 and gave the stock an "outperform" rating in a research note on Friday. Citigroup increased their price target on shares of Shattuck Labs from $4.00 to $7.00 and gave the stock a "neutral" rating in a research note on Friday, March 13th. Finally, Cantor Fitzgerald assumed coverage on shares of Shattuck Labs in a research note on Monday, April 27th. They set an "overweight" rating on the stock. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Shattuck Labs currently has an average rating of "Moderate Buy" and a consensus target price of $13.00.

Institutional Investors Weigh In On Shattuck Labs

Large investors have recently made changes to their positions in the business. Acadian Asset Management LLC increased its position in shares of Shattuck Labs by 27.6% in the first quarter. Acadian Asset Management LLC now owns 257,345 shares of the company's stock worth $243,000 after acquiring an additional 55,687 shares in the last quarter. Squarepoint Ops LLC increased its position in shares of Shattuck Labs by 236.4% in the fourth quarter. Squarepoint Ops LLC now owns 64,785 shares of the company's stock worth $236,000 after acquiring an additional 45,525 shares in the last quarter. Jane Street Group LLC increased its position in shares of Shattuck Labs by 2,510.8% in the second quarter. Jane Street Group LLC now owns 289,671 shares of the company's stock worth $229,000 after acquiring an additional 278,576 shares in the last quarter. EP Wealth Advisors LLC acquired a new stake in shares of Shattuck Labs in the fourth quarter worth $150,000. Finally, Invesco Ltd. acquired a new stake in shares of Shattuck Labs in the fourth quarter worth $103,000. Institutional investors and hedge funds own 58.74% of the company's stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc NASDAQ: STTK is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company's lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.